『Beta Finch - Thermo Fisher - TMO - EN』のカバーアート

Beta Finch - Thermo Fisher - TMO - EN

Beta Finch - Thermo Fisher - TMO - EN

著者： Beta Finch
無料で聴く

AI-powered earnings call analysis for Thermo Fisher Scientific (TMO). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch 個人ファイナンス 経済学
エピソード
  • Thermo Fisher Scientific Q2 2026 Earnings Analysis

    Thermo Fisher Scientific Q2 2026 Earnings Analysis
    2026/07/23
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **Beta Finch: Thermo Fisher Scientific (TMO) Q2 2026 Earnings Breakdown**

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Thermo Fisher Scientific's second quarter 2026 results, and Jordan, this is a genuinely strong print to sink our teeth into.

    JORDAN: Before we get into it, quick disclaimer for everyone listening. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Right, with that out of the way, let's talk numbers. Thermo Fisher posted revenue of $11.99 billion, up 10% year-over-year. Adjusted operating income jumped 15% to $2.73 billion, and adjusted EPS grew 13% to $6.03 a share.

    JORDAN: And what jumps out to me is that this wasn't a "beat on cost-cutting" quarter — this was a genuine top-line story. Organic revenue growth came in at 5%, which management explicitly said was about 2 points ahead of their own prior guidance. Margins expanded too — adjusted operating margin hit 22.8%, up 90 basis points. That's the kind of quarter where basically everything worked at once.

    ALEX: Let's break down where that growth came from. All four end markets grew mid-single-digits or better. Pharma and biotech — their biggest bucket at roughly 60% of revenue — grew mid-single digits, led by bioproduction and clinical research. Industrial and applied also grew mid-single digits, diagnostics and healthcare grew mid-single digits, and even academic and government, which has been the soft spot for a while, returned to growth, albeit low single digits.

    JORDAN: That academic and government comeback is worth sitting with for a second. CEO Marc Casper was careful not to declare victory there — he said they want to see it "more broad-based" before calling it a real trend. But the U.S. turned slightly positive, Europe was actually quite strong, and interestingly China stayed muted in that segment specifically. So it's a cautious green shoot, not a full recovery.

    ALEX: Speaking of China — it's about 7.5% of total revenue and grew low single digits, which is its first return to growth in a while. Casper credited that to pharma/biotech and industrial and applied demand, while academic spending there remains flat. He was clear it's not yet accretive to overall company growth, but the trajectory is improving.

    JORDAN: Now let's talk capital moves, because there's a lot going on here. Thermo Fisher closed the Clario acquisition in late March — that's digital clinical trial endpoint data — and it had a strong first full quarter of ownership. They also closed the filtration and separation business, formerly part of 3M/Solventum, which is showing strong demand and they're actually adding capacity.

    ALEX: And on the flip side, they're divesting their microbiology business, expected to close in Q3. That business did about $645 million in revenue in 2025. They used the anticipated proceeds to fund a $1 billion share buyback in the quarter — so essentially pre-funding the repurchase ahead of the deal closing.

    JORDAN: That divestiture does create some near-term drag, worth flagging for anyone modeling this out — management said it reduces 2026 revenue by about $200 million net of retained channel sales, and dings adjusted EPS by about $0.05 this year, growing to roughly $0.15 dilutive in the first full year after close.

    ALEX: Which makes the guidance raise even more impressive, because it absorbs that headwind and still goes up. New revenue guidance is $47.4 to $48.1 billion, representing 6-8% reported growth. Organic growth guidance moved to "about 4%" for the full year — they kept the 3-4% range but said they now expect to land at the top of it. Adjusted EPS guidance rose to $24.93 to $2

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Thermo Fisher Scientific Q1 2026 Earnings Analysis

    Thermo Fisher Scientific Q1 2026 Earnings Analysis
    2026/04/24
    **BETA FINCH PODCAST SCRIPT**

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that matter. I'm Alex.

    JORDAN: And I'm Jordan. Today we're diving into Thermo Fisher Scientific's Q1 2026 earnings, and let me tell you, this one's got some interesting moving parts.

    ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Absolutely. So Alex, TMO just reported their first quarter results, and on the surface, it looks like a pretty solid performance. What caught your attention first?

    ALEX: Well, the headline numbers are decent but not spectacular. Revenue grew 6% to $11.01 billion, and adjusted EPS came in at $5.44, also up 6%. But here's the kicker - they actually beat their own guidance by 14 cents per share on the earnings side.

    JORDAN: That's a nice beat. And they're raising full-year guidance too, right? New revenue range of $47.3 to $48.1 billion, up from the previous $46.3 to $47.2 billion range.

    ALEX: Exactly. And on earnings, they're now expecting $24.64 to $25.12 per share, up from their original $24.22 to $24.80 guide. That represents 8% to 10% growth for the year. But Jordan, there's a big asterisk here - a lot of this guidance raise comes from their massive Clario acquisition.

    JORDAN: Right, the $9 billion elephant in the room. They closed that deal in late March. Clario is a digital endpoint data solutions company that complements their clinical research business. Even though it was only in the results for a few days, it contributed $30 million in revenue and a penny per share to Q1.

    ALEX: And CEO Marc Casper was pretty excited about it on the call. He kept talking about how it enhances their "trusted partner status" with pharma and biotech customers. The integration seems to be going smoothly, and customers are apparently enthusiastic about combining Thermo's capabilities with Clario's digital endpoints technology.

    JORDAN: Speaking of pharma and biotech, that was actually their strongest end market in the quarter with mid-single digit growth. Casper highlighted strength in bioproduction and clinical research. But let's talk about the headwinds they're facing.

    ALEX: Yeah, this is where it gets interesting. They had some real operational challenges. First, they had one less selling day compared to last year, which dinged organic growth by about a percentage point. Then there was revenue phasing in pharma services - another roughly one-point headwind.

    JORDAN: So if you normalize for those factors, their 1% organic growth in Q1 would have been closer to 3%. And that's exactly what they're guiding for in Q2. The concern from analysts on the call was about this acceleration they need in the back half of the year to hit their full-year 3-4% organic growth target.

    ALEX: Casper seemed pretty confident though. He said the markets are playing out exactly as expected, and the ramp isn't really assuming any change in underlying market conditions. It's more about these timing issues and comparisons normalizing.

    JORDAN: Let's break down the segments because there were some real divergences. Life Sciences Solutions was the star with 13% reported growth, though only 1% organic. That was driven by their bioproduction business having "another quarter of excellent organic growth," as CFO Stephen Williamson put it.

    ALEX: Meanwhile, Analytical Instruments was flat on revenue with organic declining 2%. This is the ongoing story we've been hearing across the industry - weak academic and government spending, especially in the US and China. Margins in that segment got hit hard, down 250 basis points to 20.7%.

    JORDAN: Ouch. And a lot of that margin pressure was from tariffs and foreign exchange headwinds. Williamson quantified the tariff

    This episode includes AI-generated content.
    続きを読む 一部表示
    9 分
  • Thermo Fisher Scientific Q4 2025 Earnings Analysis

    Thermo Fisher Scientific Q4 2025 Earnings Analysis
    2026/02/24
    **BETA FINCH PODCAST SCRIPT**

    ---

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into Thermo Fisher Scientific's Q4 2025 results. Before we get started, I want to remind everyone that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Thanks Alex. And what a quarter to analyze! Thermo Fisher just delivered some really solid numbers to cap off 2025, plus they dropped a massive $9 billion acquisition announcement. There's a lot to unpack here.

    **ALEX:** Absolutely. Let's start with the headline numbers, Jordan. Q4 revenue came in at $12.21 billion, up 7% year-over-year. For the full year, they hit $44.56 billion in revenue, growing 4%. But here's what I found interesting - their adjusted EPS grew 8% in the quarter to $6.57, and 5% for the full year to $22.87.

    **JORDAN:** That EPS growth is noteworthy because it shows they're managing their operations really well despite some headwinds. CEO Marc Casper mentioned they faced over 100 basis points of margin pressure from tariffs and foreign exchange impacts. Yet they still delivered solid earnings growth - that's the power of their PPI business system at work.

    **ALEX:** Speaking of headwinds, let's talk about how different end markets performed. Pharma and biotech was the standout - high single-digit growth in Q4 and mid-single digits for the full year. That's their core market, so seeing strength there is crucial.

    **JORDAN:** Right, and Casper gave some really interesting color on customer sentiment in pharma during the Q&A. He talked about meeting with pharma CEOs who were much more optimistic, saying the tone in January customer meetings was "quite positive." He even shared this great anecdote about a pharma CEO who was so engaged in their discussion that he literally went and found his head of development mid-conversation to dive deeper into specifics.

    **ALEX:** That's the kind of customer relationship that's hard to quantify but incredibly valuable. It speaks to their "trusted partner" positioning. But not all end markets were as rosy - academic and government declined low single digits both for the quarter and full year, largely due to macro conditions in the US and China.

    **JORDAN:** Yeah, and that's reflected in their 2026 guidance assumptions. They're basically planning for similar market conditions to 2025, which seems prudent. They're guiding for 3-4% organic growth and 4-6% reported revenue growth, targeting $46.3 to $47.2 billion in revenue.

    **ALEX:** The earnings guidance is where things get interesting though. They're projecting 6-8% adjusted EPS growth, hitting $24.22 to $24.80 per share. That's pretty strong earnings leverage even with modest revenue growth.

    **JORDAN:** Exactly, and that doesn't even include the potential impact from their big acquisition announcement - Clario. This is a $9 billion deal for a digital endpoint data provider that generated about $1.5 billion in 2025 revenue. If it closes by year-end as expected, it could add another $0.45 in adjusted EPS.

    **ALEX:** Let's dig into that Clario deal because it's fascinating strategically. They're essentially buying capabilities in one of the fastest-growing areas of clinical research - digital endpoints for clinical trials. This fits perfectly with their "Accelerated Drug Development" solution that combines their pharma services and clinical research businesses.

    **JORDAN:** And Casper was really enthusiastic about this during the call. He talked about how it will enable "even deeper clinical insights" and "further accelerate the digital transformation of clinical research." Plus, they mentioned it has an attractive double-digit return profile and will be accretive to both organic growth and margins.

    **AL

    This episode includes AI-generated content.
    続きを読む 一部表示
    9 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません